Literature DB >> 8853832

Granisetron shows no pro-arrhythmic effect in normal subjects during or after exercise in a hot environment.

G W Gray1, T M McLellan, M B Ducharme.   

Abstract

BACKGROUND: 5-HT3 receptor antagonists are being evaluated as possible agents to prevent nausea and vomiting associated with radiation exposure in a non-clinical military setting. Because of concern about potential cardiovascular toxicity and the observation that certain developmental 5-HT3 antagonists produced undesirable effects, all drugs in this class are being carefully scrutinized for possible adverse cardiac effects.
METHOD: In this study, nine subjects underwent ambulatory ECG monitoring for an average of 21.6 h after a 2-mg oral dose of granisetron or placebo in a double-blind crossover protocol. Monitoring included a 3-h period of submaximal exercise in a 40 degrees C environment.
RESULTS: Although isolated ventricular and supraventricular ectopic activity, sinus bradycardia, and pauses were found, there were no sustained arrhythmias observed in either the placebo or granisetron conditions.
CONCLUSION: Although the generalizability of this study is limited by the small number of subjects, these observations add to the body of evidence confirming the lack of cardiovascular toxicity of granisetron.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8853832

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  5 in total

1.  Cardiac effects of granisetron in a prospective crossover randomized dose comparison trial.

Authors:  F B Cakir; O Yapar; C Canpolat; F Akalin; S G Berrak
Journal:  Support Care Cancer       Date:  2012-01-13       Impact factor: 3.603

2.  An evaluation of potential signals for ventricular arrhythmia and cardiac arrest with dolasetron, ondansetron, and granisetron in the fda combined spontaneous reporting system/adverse event reporting system.

Authors:  Frederick M Schnell; Andrew J Coop
Journal:  Curr Ther Res Clin Exp       Date:  2005-09

3.  Electrocardiographic findings of palonosetron in cancer patients.

Authors:  Guzin Gonullu; Sabri Demircan; Mustafa Kemal Demirag; Dilek Erdem; Idris Yucel
Journal:  Support Care Cancer       Date:  2011-07-20       Impact factor: 3.603

4.  Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study.

Authors:  C Yavas; U Dogan; G Yavas; M Araz; O Yavas Ata
Journal:  Support Care Cancer       Date:  2011-12-15       Impact factor: 3.603

5.  The acute effect of tropisetron on ECG parameters in cancer patients.

Authors:  Ozlem Yavas; Mehmet Yazici; Onder Eren; Cem Boruban; Mehmet Artac; Mine Genc
Journal:  Support Care Cancer       Date:  2008-02-01       Impact factor: 3.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.